Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease
Identifieur interne : 001813 ( Main/Corpus ); précédent : 001812; suivant : 001814Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease
Auteurs : Marc J. Mentis ; Dominique Delalot ; Hassan Naqvi ; Mark F. Gordon ; Mark Gudesblatt ; Christine Edwards ; Luke Donatelli ; Vijay Dhawan ; David EidelbergSource :
- Movement Disorders [ 0885-3185 ] ; 2006-04.
English descriptors
Abstract
Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double‐blind, placebo‐controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20706
Links to Exploration step
ISTEX:45B31173229AD81B750409125CE15926B5E36D47Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title><author><name sortKey="Mentis, Marc J" sort="Mentis, Marc J" uniqKey="Mentis M" first="Marc J." last="Mentis">Marc J. Mentis</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Delalot, Dominique" sort="Delalot, Dominique" uniqKey="Delalot D" first="Dominique" last="Delalot">Dominique Delalot</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Naqvi, Hassan" sort="Naqvi, Hassan" uniqKey="Naqvi H" first="Hassan" last="Naqvi">Hassan Naqvi</name><affiliation><mods:affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Gordon, Mark F" sort="Gordon, Mark F" uniqKey="Gordon M" first="Mark F." last="Gordon">Mark F. Gordon</name><affiliation><mods:affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Gudesblatt, Mark" sort="Gudesblatt, Mark" uniqKey="Gudesblatt M" first="Mark" last="Gudesblatt">Mark Gudesblatt</name><affiliation><mods:affiliation>Neurology, South Shore Associates, Bay Shore, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Edwards, Christine" sort="Edwards, Christine" uniqKey="Edwards C" first="Christine" last="Edwards">Christine Edwards</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Donatelli, Luke" sort="Donatelli, Luke" uniqKey="Donatelli L" first="Luke" last="Donatelli">Luke Donatelli</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:45B31173229AD81B750409125CE15926B5E36D47</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20706</idno><idno type="url">https://api.istex.fr/document/45B31173229AD81B750409125CE15926B5E36D47/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001813</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title><author><name sortKey="Mentis, Marc J" sort="Mentis, Marc J" uniqKey="Mentis M" first="Marc J." last="Mentis">Marc J. Mentis</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Delalot, Dominique" sort="Delalot, Dominique" uniqKey="Delalot D" first="Dominique" last="Delalot">Dominique Delalot</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Naqvi, Hassan" sort="Naqvi, Hassan" uniqKey="Naqvi H" first="Hassan" last="Naqvi">Hassan Naqvi</name><affiliation><mods:affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Gordon, Mark F" sort="Gordon, Mark F" uniqKey="Gordon M" first="Mark F." last="Gordon">Mark F. Gordon</name><affiliation><mods:affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Gudesblatt, Mark" sort="Gudesblatt, Mark" uniqKey="Gudesblatt M" first="Mark" last="Gudesblatt">Mark Gudesblatt</name><affiliation><mods:affiliation>Neurology, South Shore Associates, Bay Shore, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Edwards, Christine" sort="Edwards, Christine" uniqKey="Edwards C" first="Christine" last="Edwards">Christine Edwards</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Donatelli, Luke" sort="Donatelli, Luke" uniqKey="Donatelli L" first="Luke" last="Donatelli">Luke Donatelli</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04">2006-04</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="549">549</biblScope><biblScope unit="page" to="555">555</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">45B31173229AD81B750409125CE15926B5E36D47</idno><idno type="DOI">10.1002/mds.20706</idno><idno type="ArticleID">MDS20706</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>human</term><term>motor task</term><term>positron emission tomography</term><term>psychophysics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double‐blind, placebo‐controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Marc J. Mentis MD</name><affiliations><json:string>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item><json:item><name>Dominique Delalot MA</name><affiliations><json:string>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item><json:item><name>Hassan Naqvi MD</name><affiliations><json:string>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item><json:item><name>Mark F. Gordon MD</name><affiliations><json:string>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item><json:item><name>Mark Gudesblatt MD</name><affiliations><json:string>Neurology, South Shore Associates, Bay Shore, New York, USA</json:string></affiliations></json:item><json:item><name>Christine Edwards MA</name><affiliations><json:string>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item><json:item><name>Luke Donatelli BA</name><affiliations><json:string>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item><json:item><name>Vijay Dhawan PhD</name><affiliations><json:string>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item><json:item><name>David Eidelberg MD</name><affiliations><json:string>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>positron emission tomography</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>motor task</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psychophysics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>human</value></json:item></subject><articleId><json:string>MDS20706</json:string></articleId><language><json:string>eng</json:string></language><abstract>Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double‐blind, placebo‐controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>7.304</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1329</abstractCharCount><pdfWordCount>5076</pdfWordCount><pdfCharCount>32494</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>192</abstractWordCount></qualityIndicators><title>Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>21</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>555</last><first>549</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.20706</json:string></doi><id>45B31173229AD81B750409125CE15926B5E36D47</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/45B31173229AD81B750409125CE15926B5E36D47/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/45B31173229AD81B750409125CE15926B5E36D47/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/45B31173229AD81B750409125CE15926B5E36D47/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><notesStmt><note>Pfizer Inc.</note><note>American Parkinson's Disease Association</note><note>National Institutes of Health - No. K23 NS02204; No. NS K24 02101;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title><author><persName><forename type="first">Marc J.</forename><surname>Mentis</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Center for Neurosciences, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030</p></note><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author><author><persName><forename type="first">Dominique</forename><surname>Delalot</surname></persName><roleName type="degree">MA</roleName><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author><author><persName><forename type="first">Hassan</forename><surname>Naqvi</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author><author><persName><forename type="first">Mark F.</forename><surname>Gordon</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author><author><persName><forename type="first">Mark</forename><surname>Gudesblatt</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurology, South Shore Associates, Bay Shore, New York, USA</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Edwards</surname></persName><roleName type="degree">MA</roleName><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author><author><persName><forename type="first">Luke</forename><surname>Donatelli</surname></persName><roleName type="degree">BA</roleName><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author><author><persName><forename type="first">Vijay</forename><surname>Dhawan</surname></persName><roleName type="degree">PhD</roleName><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author><author><persName><forename type="first">David</forename><surname>Eidelberg</surname></persName><roleName type="degree">MD</roleName><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04"></date><biblScope unit="volume">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="549">549</biblScope><biblScope unit="page" to="555">555</biblScope></imprint></monogr><idno type="istex">45B31173229AD81B750409125CE15926B5E36D47</idno><idno type="DOI">10.1002/mds.20706</idno><idno type="ArticleID">MDS20706</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double‐blind, placebo‐controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>positron emission tomography</term></item><item><term>motor task</term></item><item><term>psychophysics</term></item><item><term>Parkinson's disease</term></item><item><term>human</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-11-16">Received</change><change when="2005-06-24">Registration</change><change when="2006-04">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/45B31173229AD81B750409125CE15926B5E36D47/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v21:4</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2006-04">April 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="190" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20706</doi><idGroup><id type="unit" value="MDS20706"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-11-16"></event><event type="manuscriptRevised" date="2005-05-12"></event><event type="manuscriptAccepted" date="2005-06-24"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-10-14"></event><event type="firstOnline" date="2005-10-14"></event><event type="publishedOnlineFinalForm" date="2006-04-11"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">549</numbering><numbering type="pageLast">555</numbering></numberingGroup><correspondenceTo>Center for Neurosciences, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20706.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="35"></count><count type="wordTotal" number="4972"></count></countGroup><titleGroup><title type="main" xml:lang="en">Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title><title type="short" xml:lang="en">Anticholinesterase Effect on Movement in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Marc J.</givenNames><familyName>Mentis</familyName><degrees>MD</degrees></personName><contactDetails><email>mentis@nshs.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Dominique</givenNames><familyName>Delalot</familyName><degrees>MA</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Hassan</givenNames><familyName>Naqvi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Mark F.</givenNames><familyName>Gordon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Mark</givenNames><familyName>Gudesblatt</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christine</givenNames><familyName>Edwards</familyName><degrees>MA</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Luke</givenNames><familyName>Donatelli</familyName><degrees>BA</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Vijay</givenNames><familyName>Dhawan</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>David</givenNames><familyName>Eidelberg</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Neurology, South Shore Associates, Bay Shore, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">positron emission tomography</keyword><keyword xml:id="kwd2">motor task</keyword><keyword xml:id="kwd3">psychophysics</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">human</keyword></keywordGroup><fundingInfo><fundingAgency>Pfizer Inc.</fundingAgency></fundingInfo><fundingInfo><fundingAgency>American Parkinson's Disease Association</fundingAgency></fundingInfo><fundingInfo><fundingAgency>National Institutes of Health</fundingAgency><fundingNumber>K23 NS02204</fundingNumber><fundingNumber>NS K24 02101</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double‐blind, placebo‐controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Anticholinesterase Effect on Movement in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Marc J.</namePart><namePart type="family">Mentis</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><description>Correspondence: Center for Neurosciences, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dominique</namePart><namePart type="family">Delalot</namePart><namePart type="termsOfAddress">MA</namePart><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hassan</namePart><namePart type="family">Naqvi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark F.</namePart><namePart type="family">Gordon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Center, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark</namePart><namePart type="family">Gudesblatt</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurology, South Shore Associates, Bay Shore, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Edwards</namePart><namePart type="termsOfAddress">MA</namePart><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Luke</namePart><namePart type="family">Donatelli</namePart><namePart type="termsOfAddress">BA</namePart><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vijay</namePart><namePart type="family">Dhawan</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Eidelberg</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Neurosciences, North Shore–LIJ Health System, New Hyde Park, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-04</dateIssued><dateCaptured encoding="w3cdtf">2004-11-16</dateCaptured><dateValid encoding="w3cdtf">2005-06-24</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">35</extent><extent unit="words">4972</extent></physicalDescription><abstract lang="en">Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double‐blind, placebo‐controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity. © 2005 Movement Disorder Society</abstract><note type="funding">Pfizer Inc.</note><note type="funding">American Parkinson's Disease Association</note><note type="funding">National Institutes of Health - No. K23 NS02204; No. NS K24 02101; </note><subject lang="en"><genre>Keywords</genre><topic>positron emission tomography</topic><topic>motor task</topic><topic>psychophysics</topic><topic>Parkinson's disease</topic><topic>human</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>549</start><end>555</end><total>7</total></extent></part></relatedItem><identifier type="istex">45B31173229AD81B750409125CE15926B5E36D47</identifier><identifier type="DOI">10.1002/mds.20706</identifier><identifier type="ArticleID">MDS20706</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001813 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001813 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:45B31173229AD81B750409125CE15926B5E36D47
|texte= Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |